Guardant Health, Inc.
Guardant Health, Inc. (GH) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Guardant Health, Inc. (GH), featuring income statements, balance sheets, and cash flow data.
Guardant Health, Inc. (GH) Income Statement & Financial Overview
View the income breakdown for Guardant Health, Inc. GH across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $203.47M | $201.81M | $191.48M | $177.24M |
| Cost of Revenue | $74.72M | $77.59M | $74.49M | $72.42M |
| Gross Profit | $128.75M | $124.22M | $116.99M | $104.81M |
| Gross Profit Ratio | $0.63 | $0.62 | $0.61 | $0.59 |
| R&D Expenses | $88.52M | $93.54M | $87.31M | $83.10M |
| SG&A Expenses | $151.27M | $156.64M | $147.009M | $122.33M |
| Operating Expenses | $239.79M | $250.19M | $234.31M | $205.43M |
| Total Costs & Expenses | $314.51M | $327.78M | $308.80M | $277.85M |
| Interest Income | $9.11M | $11.65M | $13.26M | $13.91M |
| Interest Expense | $791000.00 | $645000.00 | $646000.00 | $645000.00 |
| Depreciation & Amortization | -$15.38M | $10.45M | $10.60M | $10.70M |
| EBITDA | -$111.04M | -$99.19M | -$96.48M | -$91.15M |
| EBITDA Ratio | -$0.55 | -$0.49 | -$0.50 | -$0.51 |
| Operating Income | -$111.04M | -$125.97M | -$117.33M | -$100.62M |
| Operating Income Ratio | -$0.55 | -$0.62 | -$0.61 | -$0.57 |
| Other Income/Expenses (Net) | $16.17M | $15.68M | $9.60M | -$1.88M |
| Income Before Tax | -$94.87M | -$110.29M | -$107.72M | -$102.50M |
| Income Before Tax Ratio | -$0.47 | -$0.55 | -$0.56 | -$0.58 |
| Income Tax Expense | $290000.00 | $716000.00 | $30000.00 | $133000.00 |
| Net Income | -$95.16M | -$111.006M | -$107.75M | -$102.63M |
| Net Income Ratio | -$0.47 | -$0.55 | -$0.56 | -$0.58 |
| EPS | -$0.77 | -$0.90 | -$0.88 | -$0.84 |
| Diluted EPS | -$0.77 | -$0.90 | -$0.88 | -$0.84 |
| Weighted Avg Shares Outstanding | $123.87M | $123.75M | $123.05M | $122.45M |
| Weighted Avg Shares Outstanding (Diluted) | $123.87M | $123.75M | $123.05M | $122.45M |
Financial performance has remained strong, with revenue growing from $177.24M in Q2 2024 to $203.47M in Q1 2025. Gross profit continued to perform well, with margins at 63% in the latest quarter. Operating income reached -$111.04M in Q1 2025, holding a steady -55% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$111.04M. Net income rose to -$95.16M, keeping EPS at -$0.77. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan